Discovery of Novel N-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma
Lists
Only you see this
Abstract
Targeting tumor stemness is an innovative approach to cancer treatment. Zinc Finger Protein 207 (ZNF207) is a promising target for weakening the stemness of glioma cells. Here, a series of novel <i>N</i>-(anthracen-9-ylmethyl) benzamide derivatives against ZNF207 were rationally designed and synthesized. The inhibitory activity was evaluated, and their structure-activity relationships were summarized. Among them, <b>C16</b> exhibited the most potent inhibitory activity, as evidenced by its IC<sub>50</sub> values ranging from 0.5-2.5 μM for inhibiting sphere formation and 0.5-15 μM for cytotoxicity. Furthermore, we found that <b>C16</b> could hinder tumorigenesis and migration and promote apoptosis <i>in vitro</i>. These effects were attributed to the downregulation of stem-related genes. The <i>in vivo</i> evaluation demonstrated that <b>C16</b> exhibited efficient permeability across the blood-brain barrier and potent efficacy in both subcutaneous and orthotopic glioma tumor models. Hence, <b>C16</b> may serve as a potential lead compound targeting ZNF207 and has promising therapeutic potential for glioma.
BibTeX
@article{zhang2024discovery,
author = {Menghan Zhang and Yushi Ding and Mengkang Gao and Xiaolin Lü and Jun Tan and Fei Yu and Congying Gu and Lujun Gu and Xiameng Ren and Chenyan Hao and Liqin Ming and Kang Xu and Wenhao Mao and Yuqing Jin and Min Zhang and Linjun You and Zhanbo Wang and Yuanyuan Sun and Jingwei Jiang and Yong Yang and Dayong Zhang and Xin‐Ying Tang},
title = {{Discovery of Novel <i>N</i>-(Anthracen-9-ylmethyl) Benzamide Derivatives as ZNF207 Inhibitors Promising in Treating Glioma}},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02241},
}Loading related content...